Uppsala, Sweden 8/29/11—Investment firm nxt2b has agreed to acquire a 49% ownership share in Olink for an undisclosed amount. Olink Bioscience’s Duolink products are used for the visualization and quantification of individual proteins and their interactions and modifications in unmodified cells and tissues. Founded in 2004, Olink has 25 employees. “Together with nxt2b, we have now created a foundation to take Olink to new levels of commercial success by combining our unique portfolio of technologies and products with the experience and financial strength of nxt2b,” stated Olink President and CEO Björn Ekström.